PMT for MDRO Decolonization
NCT05632315
Bacterial Infections, Bacterial Infections and Mycoses
Atlanta, Georgia, United States
View Trial DetailsNCT Number: NCT05282082
Pseudomonas aeruginosa causes severe infections in hospitalized patients. The worldwide emergence of carbapenem-resistant P. aeruginosa (CRPA) makes infections by these pathogens almost untreatable. The World Health Organization now ranks CRPA highest in the list of 'urgent threats'. Information for action to prevent further emergence has to come from insight into sources and transmission routes through smart surveillance. At present, a smart surveillance strategy is not available for CRPA. The aim of this project is to develop a globally-applicable smart surveillance strategy to guide action against the spread of CRPA. Since P. aeruginosa prefers moist niches, we will focus on the human-water interface. First, highly-sensitive methods to detect CRPA in specific environmental and human niches will be developed. Subsequently, CRPA will be collected in three study sites with increasing prevalences of CRPA, increasingly warmer climates, and different water situations: Rotterdam (The Netherlands), Rome (Italy), Jakarta (Indonesia). CRPA will be searched for in a variety of niches in the environment outside and inside the hospital, and in healthy humans and hospitalized patients. Whole genome sequencing will be performed to compare the CRPA from different sources and identify transmission routes. Our project will provide insight into the relative contribution of the different potential reservoirs of CRPA to its spread in different settings which will be used for the development of a globally-applicable surveillance strategy for CRPA to guide preventive actions.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Dr Cipto Mangunkusumo General Hospital, Jakarta, Indonesia
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
healthy individuals:
Exclusion criteria
healthy individuals:
Inclusion criteria
patients:
Exclusion criteria
patients:
Time frame: 2022/2024
Time frame: 2022/2024
Looking for future studies?
Notify MeErasmus Medical Center
Other
A Smart Surveillance Strategy for Carbapenem-resistant Pseudomonas Aeruginosa: the SAMPAN Study.
Acronym: SAMPAN
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05632315
Bacterial Infections, Bacterial Infections and Mycoses
Atlanta, Georgia, United States
View Trial DetailsNCT06016088
Bacterial Infections, Bacterial Infections and Mycoses
Tucson, Arizona, United States
View Trial DetailsNCT03510351
Bacterial Infections, Bacterial Infections and Mycoses
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT04171817
Bacterial Infections, Bacterial Infections and Mycoses
Baltimore, Maryland, United States
View Trial Details